|
English
|
正體中文
|
简体中文
|
总笔数 :2822924
|
|
造访人次 :
30048440
在线人数 :
1036
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"hochmair m j"的相关文件
显示项目 1-7 / 7 (共1页)
1
每页显示[10|25|50]项目
| 臺大學術典藏 |
2022-08-10T02:37:38Z |
Brigatinib Versus Crizotinib in ALK Inhibitor�VNaive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
|
Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garcia Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.I.; Gettinger S.N.; Tiseo M.; Lin H.M.; Liu Y.; Vranceanu F.; Niu H.; Zhang P.; Popat S. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor�VNaive ALK-Positive Non�VSmall Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
|
Camidge D.R.;Kim H.R.;Ahn M.-J.;Chih-Hsin Yang;Han J.-Y.;Hochmair M.J.;Lee K.H.;Delmonte A.;Garc?A Campelo M.R.;Kim D.-W.;Griesinger F.;Felip E.;Califano R.;Spira A.;Gettinger S.N.;Tiseo M.;Lin H.M.;Gupta N.;Hanley M.J.;Ni Q.;Zhang P.;Popat S.; Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garc?a Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.; Gettinger S.N.; Tiseo M.; Lin H.M.; Gupta N.; Hanley M.J.; Ni Q.; Zhang P.; Popat S. |
| 臺大學術典藏 |
2021-04-23T05:56:26Z |
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Final analysis of the GioTag study
|
Hochmair M.J.;Morabito A.;Hao D.;Yang C.-T.;Soo R.A.;Chih-Hsin Yang;Gucalp R.;Halmos B.;M?Rten A.;Cufer T.; Hochmair M.J.; Morabito A.; Hao D.; Yang C.-T.; Soo R.A.; CHIH-HSIN YANG; Gucalp R.; Halmos B.; M?rten A.; Cufer T. |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study
|
Märten A; Cufer T.; Cufer T.;M?rten A;Golembesky A;Wang L;Halmos B;Gucalp R;Chih-Hsin Yang;Soo R.A;Yang C.-T;Hao D;Morabito A;Hochmair M.J; Hochmair M.J; Morabito A; Hao D; Yang C.-T; Soo R.A; CHIH-HSIN YANG; Gucalp R; Halmos B; Wang L; Golembesky A |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
|
Popat S.;Kerstein D;Haney J;Gupta N;Tiseo M;Gettinger S.N;Spira A;Ghosh S;Califano R;Felip E;Morabito A;Griesinger F;Bearz A;Kim D.-W;Garcia Campelo R;Delmonte A;Gridelli C;Lee K.H;Chang G.-C;Li J.Y.-C;Hochmair M.J;Lee J.-S;Han J.-Y;Chih-Hsin Yang;Ahn M.-J;Kim H.R;Camidge D.R; Camidge D.R; Kim H.R; Ahn M.-J; CHIH-HSIN YANG; Han J.-Y; Lee J.-S; Hochmair M.J; Li J.Y.-C; Chang G.-C; Lee K.H; Gridelli C; Delmonte A; Garcia Campelo R; Kim D.-W; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger S.N; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S. |
| 臺大學術典藏 |
2020-05-26T09:26:23Z |
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study
|
Cufer T.; Märten A; Wang L; Halmos B; Gucalp R; CHIH-HSIN YANG; Soo R.A; Yang C.-T; Hao D; Hochmair M.J;Morabito A;Hao D;Yang C.-T;Soo R.A;Chih-Hsin Yang;Gucalp R;Halmos B;Wang L;M?rten A;Cufer T.; Hochmair M.J; Morabito A |
| 國立臺灣大學 |
2015 |
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
|
Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; O'Byrne, K.; Okamoto, I.; Schuler, M.; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Maerten, A.; Wind, S.; Carbone, D. P.; 楊志新 |
显示项目 1-7 / 7 (共1页)
1
每页显示[10|25|50]项目
|
